Second-generation antipsychotics for obsessive compulsive disorder
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obsessive compulsive disorder (OCD) is a psychiatric disorder which has been shown to affect 2 to 3.5% of people during their lifetimes. Inadequate response occurs in 40% to 60% of people that are prescribed first line pharmaceutical treatments (selective serotonin reuptake inhibitors (SSRIs)). To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs (SGAs) in people suffering from OCD. OBJECTIVES: To evaluate the effects of SGAs (monotherapy or add on) compared with placebo or other forms of pharmaceutical treatment for people with OCD. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on ClinicalTrials.gov and contacted key authors and drug companies. SELECTION CRITERIA: We included double-blind randomised controlled trials (RCTs) comparing oral SGAs (monotherapy or add on) in adults with other forms of pharmaceutical treatment or placebo in people with primary OCD. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated the odds ratio (OR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated mean differences (MD), again based on a random-effects model. MAIN RESULTS: We included 11 RCTs with 396 participants on three SGAs. All trials investigated the effects of adding these SGAs to antidepressants (usually SSRIs). The duration of all trials was less than six months. Only 13% of the participants left the trials early. Most trials were limited in terms of quality aspects.Two trials examined olanzapine and found no difference in the primary outcome (response to treatment) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants.Quetiapine combined with antidepressants was also not any more efficacious than placebo combined with antidepressants in terms of the primary outcome, but there was a significant superiority in the mean Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score at endpoint (MD -2.28, 95% CI -4.05 to -0.52). There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms.Risperidone was more efficacious than placebo in terms of the primary outcome (number of participants without a significant response) (OR 0.17, 95% CI 0.04 to 0.66) and in the reduction of anxiety and depression (MD -7.60, 95% CI -12.37 to -2.83). AUTHORS' CONCLUSIONS: The available data of the effects of olanzapine in OCD are too limited to draw any conclusions. There is some evidence that adding quetiapine or risperidone to antidepressants increases efficacy, but this must be weighed against less tolerability and limited data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Research works printed but not linked: 40
- Geus, 2007, Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder, International Clinical Psychopharmacology, 22, 77, 10.1097/YIC.0b013e32801182f7 · DOI
- Ezegovesi, 2005, Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study, European Neuropsychopharmacology, 15, 69, 10.1016/j.euroneuro.2004.04.004 · DOI
- Kordon, 2008, Quetiapin addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 28, 550, 10.1097/JCP.0b013e318185e735 · DOI
- Baxter, 2002, Adjunctive risperidone in the treatment of SSRI-refractory obsessive-compulsive disorder, International Journal of Neuropsychopharmacology, 5, 132
- Shapira, 2004, A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder, Biological Psychiatry, 550, 553, 10.1016/j.biopsych.2003.11.010 · DOI
- Vulink, 2009, Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled study of 76 patients, Journal of Clinical Psychiatry online publication, 70, 1001, 10.4088/JCP.08m04269 · DOI
- Atmaca, 2002, Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study, International Clinical Psychopharmacology, 17, 115, 10.1097/00004850-200205000-00004 · DOI
- D'Amico, 2003, Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder, Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 619, 10.1016/S0278-5846(03)00050-2 · DOI
- Denys, 2002, Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study, Journal of Clinical Psychiatry, 63, 700, 10.4088/JCP.v63n0807 · DOI
- Koran, 2000, Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder, Journal of Clinical Psychiatry, 61, 514, 10.4088/JCP.v61n0709 · DOI
- Liu, 2005, Comparative analysis of risperidone combining with paroxetine in treatment of obsessive compulsive disorder, Journal of Clinical Psychological Medicine, 15, 17
- Maina, 2008, 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder, European Neuropsychopharmacology, 18, 364, 10.1016/j.euroneuro.2008.01.001 · DOI
- Mohr, 2002, Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder, International Clinical Psychopharmacology, 17, 37, 10.1097/00004850-200201000-00006 · DOI
- Pigott, 1992, A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 12, 11, 10.1097/00004714-199202000-00003 · DOI · Paper page
- Stein, 1997, Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders, Journal of Clinical Psychiatry, 58, 119, 10.4088/JCP.v58n0306 · DOI · Paper page
- Yang, 2002, A comparative study on the efficacy of combining risperidone and fluoxetine in the treatment of refractory obsessive compulsive disorder, Chinese Journal of Behavioural Medical Science, 11, 402
- American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III)
- American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition- Revised (DSM-III-R)
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
- Arnt, 1998, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology, 18, 63, 10.1016/S0893-133X(97)00112-7 · DOI · Paper page
- Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
- Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006531 · DOI
- Correll, 2004, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies, American Journal of Psychiatry, 161, 414, 10.1176/appi.ajp.161.3.414 · DOI · Paper page
- Der-Simonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
- Goodwin, 2009, Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus Meeting, March 2008, Nice, European Neuropsychopharmacology, 19, 520, 10.1016/j.euroneuro.2009.04.003 · DOI
- Gulliford, 1999, Components of variance and intra class correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
- Guy, 1976, Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
- Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
- Hawkridge, 2009, Pharmacotherapy for anxiety disorders in children and adolescents, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005170.pub2 · DOI · Paper page
- Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008 · DOI · Paper page
- Ipser, 2006, Pharmacotherapy augmentation strategies in treatment resistant augmentation disorders, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005473.pub2 · DOI
- Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- Ravindran, 2007, Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders, Expert Opinion in Pharmacotherapy, 8, 1693, 10.1517/14656566.8.11.1693 · DOI
- Sajatovic, 2003, Treatment for mood and anxiety disorders: quetiapine and aripiprazole, Current Psychiatry Reports, 5, 320, 10.1007/s11920-003-0062-9 · DOI
- Vital, 2007, Seroquel led antipsychotics sales in 2006, Clinical Psychiatric News, 35, 1
- World Health Organization, 1992, International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)
- Zaudig, 2002, Epidemiology, comorbidity and course of obsessive compulsive disorder
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Zohar, J., Stahl, S., Moller, H.-J., Blier, P., Kupfer, D., Yamawaki, S., Uchida, H., Spedding, M., Goodwin, G. M., & Nutt, D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.019 · Cited by 186
Abraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165
Metadata
- Authors
- Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-12-08
- Issue
- 12
- Pages
- CD008141-CD008141
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1588248498
- Cited by
- 96
- References
- 19
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second-generation antipsychotics for obsessive compulsive disorder. https://app.cochat.ai/papers/10.1002/14651858.cd008141.pub2
- The paper
- Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008141.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.